Glipizide, a small yet powerful drug from Pfizer Inc., effectively combats hyperglycemia and type 2 diabetes.

Monte Rosa Therapeutics has commenced preclinical trials for its novel compound MRT-8102, a pioneering NEK7-targeted molecular glue degrader with additional capabilities of impeding the NLRP3/IL-1β signaling cascade.

In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.

Aprea Therapeutics reveals it has received FDA authorization for its investigational new drug, APR-1051, a novel WEE1 kinase blocker targeting cancers with high Cyclin E levels.

Hydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR.

AbilityPharma Secures Funding of €7M for Progressing Phase 2b Trials of ABTL0812, an Autophagy-Stimulating Drug, in Treating Spread-Out Pancreatic Cancer.

Novo Nordisk has excelled in research and development, aiding over 40 million chronic disease patients globally.

Ranok Therapeutics broadens its clinical trials for its BRD4 protein degradation agent RNK05047, now including tests in China.

Budesonide, a small molecule drug with a strong ability to bind to the glucocorticoid receptor (GR) as an agonist, was approved as early as 1981 and has been on the market for more than 40 years.

ASLAN Pharmaceuticals Offers Update on TREK-DX Research and Emphasizes Eblasakimab's Effectiveness for Patients with Atopic Dermatitis Previously Treated with Dupilumab.

In January, Oricell Therapeutics announced U.S. FDA approval for the IND application of OriCAR-017 to treat relapsed/refractory multiple myeloma (R/R MM).

MoonLake reveals notable advancements using Nanobody® sonelokimab over a six-month period for treating active psoriatic arthritis (PsA), along with other crucial updates during its research and development event.